Technical Analysis for BLUE - bluebird bio, Inc.

Grade Last Price % Change Price Change
F 0.30 -0.69% 0.00
BLUE closed down 0.69 percent on Wednesday, November 20, 2024, on 57 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Doji - Bullish? Reversal 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -0.69%
180 Bearish Setup Bearish Swing Setup -0.69%
Lower Bollinger Band Walk Weakness -0.69%
New 52 Week Low Weakness -0.69%
Wide Bands Range Expansion -0.69%

   Recent Intraday Alerts

Alert Time
Down 3% about 17 hours ago
Down 2 % about 17 hours ago
Possible NR7 about 18 hours ago
Lower Bollinger Band Support about 18 hours ago
60 Minute Opening Range Breakdown about 19 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

bluebird bio, Inc. Description

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on the development, manufacture, and marketing of therapies to treat various human diseases. Its product candidates include Lenti-D to treat patients with childhood cerebral adrenoleukodystrophy (ALD), a hereditary neurological disorder, as well as for the treatment of adult cerebral ALD; and CAR T cells products for treating oncology diseases. The company's product candidates also comprise LentiGlobin vector for the treatment of ß-thalassemia, a hereditary blood disorder; and sickle cell diseases. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Rare Diseases Medical Genetics Dystrophy Human Diseases Summit Childhood Genetic Genealogy Sickle Cell Disease Thalassemia Iglo Oncology Diseases

Is BLUE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.53
52 Week Low 0.29
Average Volume 6,011,752
200-Day Moving Average 0.90
50-Day Moving Average 0.47
20-Day Moving Average 0.42
10-Day Moving Average 0.36
Average True Range 0.04
RSI (14) 23.66
ADX 39.96
+DI 6.08
-DI 35.08
Chandelier Exit (Long, 3 ATRs) 0.41
Chandelier Exit (Short, 3 ATRs) 0.40
Upper Bollinger Bands 0.55
Lower Bollinger Band 0.29
Percent B (%b) 0.06
BandWidth 62.52
MACD Line -0.05
MACD Signal Line -0.04
MACD Histogram -0.0104
Fundamentals Value
Market Cap 58.4 Million
Num Shares 193 Million
EPS -0.63
Price-to-Earnings (P/E) Ratio -0.48
Price-to-Sales 9.32
Price-to-Book 0.89
PEG Ratio 0.32
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.34
Resistance 3 (R3) 0.34 0.33 0.34
Resistance 2 (R2) 0.33 0.32 0.33 0.33
Resistance 1 (R1) 0.32 0.31 0.31 0.32 0.33
Pivot Point 0.30 0.30 0.30 0.30 0.30
Support 1 (S1) 0.29 0.29 0.28 0.29 0.27
Support 2 (S2) 0.28 0.29 0.28 0.27
Support 3 (S3) 0.26 0.28 0.27
Support 4 (S4) 0.26